Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001908764 | SCV002168892 | uncertain significance | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A | 2021-08-14 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with glutamine at codon 73 of the MOCS1 protein (p.Arg73Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with clinical features of molybdenum cofactor deficiency (PMID: 21031595). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant disrupts the p.Arg73 amino acid residue in MOCS1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9921896, 20573177; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |